文章摘要
庞旭阳,郝晓静,郭宏盛,郭 敏,朱海生,石小翠,王 敏,贾庆祥,卢怀海.丁苯酞联合低剂量阿替普酶治疗急性脑梗死的疗效及对患者神经内分泌因子的影响[J].,2021,(3):562-566
丁苯酞联合低剂量阿替普酶治疗急性脑梗死的疗效及对患者神经内分泌因子的影响
Clinical Efficacy and Effect of Butylphthalide Combined with Low-dose Alteplase on Neuroendocrine Factors of Patients with Acute Cerebral Infarction
投稿时间:2020-03-29  修订日期:2020-04-25
DOI:10.13241/j.cnki.pmb.2021.03.035
中文关键词: 急性脑梗死  丁苯酞  低剂量  阿替普酶  神经内分泌因子
英文关键词: Acute cerebral infarction  Butylphthalide  Low-dose  Alteplase  Neuroendocrine factor
基金项目:河北省医学科学研究重点课题计划项目(20181680)
作者单位E-mail
庞旭阳 河北省邯郸市中心医院神经内科 河北 邯郸 056001 13290486110@sina.cn 
郝晓静 河北省邯郸市中心医院神经内科 河北 邯郸 056001  
郭宏盛 河北省邯郸市中心医院神经内科 河北 邯郸 056001  
郭 敏 河北省邯郸市中心医院神经内科 河北 邯郸 056001  
朱海生 河北省邯郸市中心医院神经内科 河北 邯郸 056001  
石小翠 河北省邯郸市中心医院神经内科 河北 邯郸 056001  
王 敏 河北省邯郸市中心医院神经内科 河北 邯郸 056001  
贾庆祥 河北省邯郸市中心医院神经内科 河北 邯郸 056001  
卢怀海 河北医科大学第二医院重症医学二科 河北 石家庄 050000  
摘要点击次数: 17
全文下载次数: 32
中文摘要:
      摘要 目的:探讨丁苯酞联合低剂量阿替普酶治疗急性脑梗死的疗效及对患者神经内分泌因子的影响。方法:按照随机数表法将105例患者分为对照组(n=52)和研究组(n=53)。对照组患者采用低剂量阿替普酶治疗,研究组患者在对照组基础上加用丁苯酞治疗。评价并比较两组临床疗效,比较两组治疗前后美国国立卫生研究院卒中量表(NIHSS)评分和血清S-100蛋白(S100B)、神经元特异性烯醇化酶(NSE)、髓鞘碱性蛋白(MBP)水平,比较两组治疗14 d内的颅内出血发生率和病死率。结果:研究组的临床总有效率为94.34%(50/53),明显高于对照组的76.92%(40/52),且差异具有统计学意义(x2=6.502,P=0.011)。与治疗前相比,两组治疗后NIHSS评分均明显降低,且研究组治疗后的NIHSS评分明显低于对照组,差异有统计学意义(P<0.05)。与治疗前相比,两组治疗后血清S100B、NSE及MBP水平均明显降低(P<0.05),且研究组治疗后血清S100B、NSE及MBP水平均明显低于对照组,差异有统计学意义(P<0.05)。治疗14 d内,研究组的颅内出血发生率和死亡率均明显低于对照组,差异有统计学意义(P<0.05)。结论:丁苯酞联合低剂量阿替普酶治疗急性脑梗死的疗效显著,能够明显改善神经功能,降低神经内分泌因子水平,且安全性较好。
英文摘要:
      ABSTRACT Objective: To investigate the clinical efficacy and effect of butylphthalide combined with low-dose alteplase on neuroendocrine factors of patients with acute cerebral infarction. Methods: According to the random table method, 105 cases of patients with acute cerebral infarction were divided into the control group (n=52) and the research group (n=53). The patients in the control group were treated with low-dose alteplase, while the patients in the research group were treated with butylphthalide on the basis of the control group. The clinical efficacy of the two groups were evaluated and compared. The national institutes of health stroke scale (NIHSS) scores, serum S-100 protein (S100B), neuron-specific enolase (NSE), myelin basic protein (MBP) levels of two groups of patients before and after treatment were compared. The intracranial hemorrhage rates and mortality of the two groups during 14 days of treatment were compared. Results: The clinical efficacy rate of the research group was 94.34% (50/53), which was significantly higher than 76.92% (40/52) of the control group, and the difference was statistically significant (x2=6.502, P=0.011). Compared with before treatment, the NIHSS scores of the two groups after treatment were significantly lower, and the NIHSS scores of the research group after treatment was significantly lower than that of the control group, the difference was statistically significant (P<0.05). Compared with before treatment, the levels of serum S100B, NSE and MBP in the two groups after treatment were significantly lower (P<0.05), and the levels of serum S100B, NSE and MBP in the research group after treatment were significantly lower than those in the control group, the difference was statistically significant (P<0.05). During 14 days of treatment, the intracranial hemorrhage rates and mortality of the research group were significantly lower than those of the control group, the difference was statistically significant (P<0.05). Conclusion: The clinical curative effect of butylphthalide combined with low-dose alteplase in the treatment of patients with acute cerebral infarction is significantly, which can significantly improve the neurological function, reduce the levels of the neuroendocrine factors, and it has good safty.
查看全文   查看/发表评论  下载PDF阅读器
关闭